Olanzapine

(n = 578)

Non-olanzapine atypical antipsychotics

Typical antipsychotics

overall (n = 24)

Overall^*

(n = 487)

Risperidone

(n = 160)

Aripiprazole

(n = 154)

Blonanserin

(n = 67)

Quetiapine

(n = 44)

Paliperidone

(n = 40)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

Gender

Male

266

(46.0)

208

(42.7)

72

(45.0)

59

(38.3)

27

(40.3)

18

(40.9)

24

(60.0)

13

(54.2)

Female

312

(54.0)

279

(57.3)

88

(55.0)

95

(61.7)

40

(59.7)

26

(59.1)

16

(40.0)

11

(45.8)

p-value^F)

0.293

Age (years)

n

574

484

160

152

67

43

40

24

Mean (SD)

46.1

(15.6)

47.1

(15.9)

47.3

(16.0)

46.0

(15.5)

47.0

(16.4)

50.3

(16.9)

46.0

(15.6)

49.2

(14.0)

p-value^M)

0.295

History of schizophrenia (years)

n

404

305

95

106

39

29

22

10

Mean (SD)

14.42 (14.11)

14.43)

(13.80)

15.46

(14.40)

13.06

(12.93)

12.57

(12.38)

17.60

(15.09)

15.22

(16.07)

22.47

(10.69)

Median

10.00

10.00

10.00

8.54

10.25

12.00

6.13

19.29

Min - max

0.0 - 55.0

0.0 - 60.0

0.0 - 60.0

0.0 - 45.5

0.1 - 42.8

0.3 - 53.5

0.1 - 45.0

10.0 - 44.1

p-value^S)

0.992

Inpatient or outpatient status

Inpatient

357

(61.8)

277

(56.9)

113

(70.6)

83

(53.9)

26

(38.8)

24

(54.5)

18

(45.0)

10

(41.7)

Outpatient

221

(38.2)

210

(43.1)

47

(29.4)

71

(46.1)

41

(61.2)

20

(45.5)

22

(55.0)

14

(58.3)

p-value^F)

0.117

Living status

Single- person

household

43

(7.4)

37

(7.6)

7

(4.4)

10

(6.5)

10

(14.9)

4

(9.1)

5

(12.5)

3

(12.5)

Living with family

163

(28.2)

166

(34.1)

38

(23.8)

60

(39.0)

29

(43.3)

16

(36.4)

17

(42.5)

11

(45.8)

(0.0)

(0.0)

Living with non-family members

14

(2.4)

6

(1.2)

2

(1.3)

0

(0.0)

2

(3.0)

0

(0.0)

0

(0.0)

0

Others

1

(0.2)

1

(0.2)

0

(0.0)

1

(0.6)

0

(0.0)

0

(0.0)

0

(0.0)

0

Unknown

357

(61.8)

277

(56.9)

113

(70.6)

83

(53.9)

26

(38.8)

24

(54.5)

18

(45.0)

10

(41.7)

p-value^M)

0.284

Antipsychotics use within 1 month prior to the initiation of monotherapy

Yes

219

(37.9)

181

(37.2)

48

(30.0)

63

(40.9)

25

(37.3)

16

(36.4)

21

(52.5)

14

(58.3)

No

359

(62.1)

306

(62.8)

112

(70.0)

91

(59.1)

42

(62.7)

28

(63.6)

19

(47.5)

10

(41.7)

p-value^F)

0.849

CGI-S Parkinsonism Score^**

n

401

325

108

106

48

30

20

15

Mean (SD)

0.8

(1.5)

0.8

(1.4)

0.9

(1.5)

0.8

(1.3)

0.8

(1.5)

0.8

(1.4)

0.8

(1.3)

1.6

(2.0)

p-value^S)

0.758

Use of any anti- Parkinsonism agents^**

Yes

50

(8.7)

65

(13.3)

27

(16.9)

13

(8.4)

14

(20.9)

3

(6.8)

4

(10.0)

10

(41.7)

No

528

(91.3)

422

(86.7)

133

(83.1)

141

(91.6)

53

(79.1)

41

(93.2)

36

(90.0)

14

(58.3)

p-value^F)

0.017